UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.40 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 766.1% in the third quarter, HoldingsChannel reports. The firm owned 234,537 shares of the company’s stock after acquiring an additional 207,456 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ARS Pharmaceuticals were worth $3,401,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of SPRY. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals in the third quarter valued at about $30,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ARS Pharmaceuticals by 151.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in ARS Pharmaceuticals in the 2nd quarter valued at about $87,000. J.W. Cole Advisors Inc. raised its stake in shares of ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of ARS Pharmaceuticals during the second quarter worth approximately $180,000. Institutional investors own 68.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SPRY. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Leerink Partners raised their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $24.00.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, major shareholder James E. Flynn sold 528,456 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the sale, the insider now directly owns 5,274,735 shares in the company, valued at $95,156,219.40. This represents a 9.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Brian Dorsey sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the sale, the chief operating officer now directly owns 6,024 shares in the company, valued at $74,095.20. This trade represents a 80.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,268,058 shares of company stock valued at $19,635,686. 40.10% of the stock is currently owned by corporate insiders.

ARS Pharmaceuticals Trading Down 5.9 %

Shares of NASDAQ SPRY opened at $11.90 on Friday. The company has a market capitalization of $1.16 billion, a P/E ratio of -23.33 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12 month low of $5.02 and a 12 month high of $18.51. The stock has a 50 day moving average of $14.62 and a 200-day moving average of $12.34.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.